Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$20.21 USD

20.21
1,140,480

+0.84 (4.34%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $20.39 +0.18 (0.89%) 6:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

United Therapeutics Announces FDA Acceptance of Tyvaso sNDA

by Zacks Equity Research

United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Aquestive Therapeutics (AQST) in Focus: Stock Moves 6.4% Higher

by Zacks Equity Research

Aquestive Therapeutics (AQST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Avadel (AVDL) Surges: Stock Moves 7.8% Higher

by Zacks Equity Research

Avadel (AVDL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

by Zacks Equity Research

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

Is Pacira BioSciences (PCRX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (PCRX) Outperforming Other Medical Stocks This Year?

Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses

by Zacks Equity Research

Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.

Xeris Pharmaceuticals (XERS) Looks Good: Stock Adds 5.1% in Session

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares more than 5% on the day, amid huge volumes.

Radius' (RDUS) Q2 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research

Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.

Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line

by Zacks Equity Research

Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.

Pacira (PCRX) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of -25.00% and -0.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PCTEL (PCTI) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Despite a robust balance sheet, PCTEL (PCTI) is likely to have witnessed top- and bottom-line contractions due to COVID-19 triggered headwinds in the second quarter.

What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?

by Zacks Equity Research

Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.

Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.

CytoDyn (CYDY) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

CytoDyn's progress on its lead candidate, leronlimab, will be in focus when it reports Q4 results.

Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.

Onconova (ONTX) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on pipeline updates when Onconova (ONTX) reports Q2 results.

Teva (TEVA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 Reasons Why Pacira (PCRX) Is a Great Growth Stock

by Zacks Equity Research

Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.

Zoetis (ZTS) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Top Ranked Momentum Stocks to Buy for July 21st

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 21st

Vaxart (VXRT) Catches Eye: Stock Jumps 7.9%

by Zacks Equity Research

Vaxart (VXRT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences

by Zacks Equity Research

Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences

Nalak Das headshot

5 Stocks With Recent Price Strength Despite Market Volatility

by Nalak Das

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%

by Zacks Equity Research

Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.